Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma

Critical Reviews in Oral Biology and Medicine

Volumn 14, Issue 5, 2003, Pages 345-362

  Devaraj, Kalpana ^a   Gillison, Maura L ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cytotoxic T lymphocyte; Head and neck squamous cell carcinoma; HPV vaccines; Immunotherapy; Tumor immunology; Tumor specific antigens

Indexed keywords

ADENOVIRUS VACCINE; BCG VACCINE; CAPSID PROTEIN; DENDRITIC CELL VACCINE; DNA VACCINE; HPV 16 L1 VIRUS LIKE PARTICLE VACCINE; HPV L2 CAPSID PROTEIN VACCINE; HPV PSEUDOVIRION VACCINE; LISTERIA VACCINE; NUCLEIC ACID VACCINE; PEPTIDE VACCINE; PROTEIN E6; PROTEIN E7; RECOMBINANT VACCINE; RNA REPLICON VACCINE; SALMONELLOSIS VACCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VACCINE; VACCINIA VACCINE; VIRUS CAPSID ANTIGEN; VIRUS VACCINE; WART VIRUS VACCINE; ONCOPROTEIN; PAPILLOMA VIRUS VACCINE;

CELL TRANSFORMATION; CELLULAR IMMUNITY; CLINICAL TRIAL; GENOTYPE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; INFECTION RISK; KERATINOCYTE; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS TRANSMISSION; WART VIRUS; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; PAPILLOMA VIRUS; VIROLOGY;

CAPSID PROTEINS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; VIRAL VACCINES;

EID: 0142060273     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130301400505     Document Type: Review

References (200)

1. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, et al. (2001). Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19:2549-2556.
2. Albert ML, Sauter B, Bhardwaj N (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89.
3. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, et al. (1997). A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17-25.
4. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D (1998). Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72:8220-8229.
5. Benton C, Shahidullah H, Hunter JAA (1992). Human papillomavirus in the immunosuppressed. Papillomavirus Report 3:23-26.
6. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljestrom P (1997). Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 13:1487-1495.
7. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P (1998). Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16:562-565.
8. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. (1996). A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527.
9. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796-802.
10. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego J, Bianchi A, et al. (2000). Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 30:2281-2289.
11. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, et al. (1996). Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14:1485-1494.
12. Brandsma JL (1994). Animal models for HPV vaccine development. Papillomavirus Report 5:105-111.
13. Brandwein M, Zeitlin J, Nuovo GJ, MacConnell P, Bodian C, Urken M, et al. (1994). HPV detection using "hot start" polymerase chain reaction in patients with oral cancer: a clinicopathological study of 64 patients. Mod Pathol 7:720-727.
14. Breitburd F, Coursaget P (1999). Human papillomavirus vaccines. Semin Cancer Biol 9:431-444.
15. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. (1995). Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69:3959-3963.
16. Bubenik J, Simova J, Hajkova R, Sobota V, Jandlova T, Smahel M, et al. (1999). Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J Oncol 14:593-597.
17. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF (1993). Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74(Pt 6):945-953.
18. Cella M, Sallusto F, Lanzavecchia A (1997). Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10-16.
19. Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, et al. (2000). Antigen-specific cancer immunotherapy using an GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 86:725-730.
20. Chen CH, Wu TC (1998). Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 5:231-252.
21. Chen C-H, Wang T-L, Hung C-F, Yang Y, Young RA, Pardoll DM, et al. (2000a). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60:1035-1042.
22. Chen CH, Suh KW, Ji H, Choti MA, Pardoll DM, Wu TC (2000b). Antigen-specific immunotherapy for HPV-16 E7-expressing tumors grown in liver. J Hepatol 33:91-98.
23. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, et al. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102.
24. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP (1996). Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156:224-231.
25. Chen TT, Tao MH, Levy R (1994). Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775-4787.
26. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, et al. (2001a). Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108:669-678.
27. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Rice CM, et al. (2001b). Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166:6218-6226.
28. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Ling M, et al. (2001c). Enhancement of Sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 12:235-252.
29. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, et al. (2002). Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13:553-568.
30. Chiriva-Internati M, Liu Y, Salati E, Zhou W, Wang Z, Grizzi F, et al. (2002). Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol 32:30-38.
31. Christensen ND, Kreider JW, Kan NC, DiAngelo SL (1991). The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181:572-579.
32. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW (1996). Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70:960-965.
33. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA (2000). Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121:216-225.
34. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV (1997). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623-1631.
35. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr (1996). DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-1128.
36. Corr M, Lee DJ, Carson DA, Tighe H (1996). Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184:1555-1560.
37. Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, et al. (1997). Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 159:4999-5004.
38. Crook T, Morgenstern JP, Crawford L, Banks L (1989). Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J 8:513-519.
39. Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J (2000). Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 7:1859-1866.
40. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, et al. (1997). Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91:765-775.
41. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, et al. (1998). Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 58:724-731.
42. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG (1989). In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561-564.
43. Doan T, Herd KA, Lambert PF, Fernando GJ, Street MD, Tindle RW (2000). Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res 60:2810-2815.
44. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA (1997). DNA vaccines. Annu Rev Immunol 15:617-648.
45. Dorange F, El Mehdaoui S, Pichon C, Coursaget P, Vautherot JF (2000). Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16. J Gen Virol 81(Pt 9):2219-2230.
46. Edmonds C, Vousden KH (1989). A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol 63:2650-2656.
47. Elliott G, O'Hare P (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223-233.
48. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. (1993). Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242-2249.
49. Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH (1995). Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 13:1460-1467.
50. Flotte TR, Carter BJ (1995). Adeno-associated virus vectors for gene therapy. Gene Ther 2:357-362.
51. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL (1997). Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 123:513-516.
52. Franceschi S, Munoz N, Bosch XF, Snijders PJ, Walboomers JM (1996). Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 5:567-575.
53. Frisch M, Biggar RJ, Goedert JJ (2000a). Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92:1500-1510.
54. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ (2000b). Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 11:489-495.
55. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, et al. (1994). Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol 75:157-164.
56. Gerard CM, Baudson N, Kraemer K, Bruck C, Garcon N, Paterson Y, et al. (2001). Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19:2583-2589.
57. Gerber S, Lane C, Brown DM, Lord E, DiLorenzo M, Clements JD, et al. (2001). Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 75:4752-4760.
58. Gillison ML, Shah KV (2001). Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13:183-188.
59. Gillison ML, Koch WM, Shah KV (1999). Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Curr Opin Oncol 11:191-199.
60. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720.
61. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, et al. (1998). Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805.
62. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y (2001). Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167:6471-6479.
63. Hagensee ME, Yaegashi N, Galloway DA (1993). Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315-322.
64. Hagensee ME, Carter JJ, Wipf GC, Galloway DA (1995). Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 206:174-182.
65. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, et al. (1999). Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 81:428-437.
66. Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH (1986). Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 68:251-258.
67. Hariharan K, Braslawsky G, Barnett RS, Berquist LG, Huynh T, Hanna N, et al. (1998a). Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 12:1229-1235.
68. Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, Belli BA, et al. (1998b). DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 72:950-958.
69. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. (2001). Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93:284-292.
70. Hart DN (1997). Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90:3245-3287.
71. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, et al. (2000). Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270:146-161.
72. Heck DV, Yee CL, Howley PM, Munger K (1992). Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89:4442-4446.
73. Heufler C, Koch F, Schuler G (1988). Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 167:700-705.
74. Hsu KF, Hung KF, Cheng WF, He L, Ling MF, Wu TC (2001). Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Therapy 8:376-383.
75. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965.
76. Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, et al. (2001a). Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 166:5733-5740.
77. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, et al. (2001b). Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61:3698-3703.
78. Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC (2002). Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 76:2676-2682.
79. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702.
80. Irvine KR, Rao JB, Rosenberg SA, Restifo NP (1996). Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238-245.
81. Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K, et al. (2000). Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 18:2444-2453.
82. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, et al. (1995). Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13:1509-1514.
83. Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ (1992). Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 66:1329-1335.
84. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC (1998). Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 78:41-45.
85. Ji H, Wang T-L, Chen C-H, Hung C-F, Pai S, Lin K-Y, et al. (1999). Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum Gene Ther 10:2727-2740.
86. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L (1999). Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 30:269-274.
87. Kashima H, Mounts P, Leventhal B, Hruban RH (1993). Sites of predilection in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 102:580-583.
88. Kast WM, Brandt R, Drijfhout JW, Melief C (1993). Human leukocyte antigen-A2.1 restricted candidate cytotoxic T-lymphocyte epitopes of human papillomavirus type-16 E6-protein and E7-protein identified by using the processing-defective human cell line-T2. J Immunother 14:115-120.
89. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T (1999). Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73:6188-6190.
90. Kawana K, Kawana Y, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T (2001). Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicits systemic and mucosal antibodies. Vaccine 19:1496-1502.
91. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. (1993). Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67:6929-6936.
92. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, et al. (1996). Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37-44.
93. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651.
94. Krul MR, Tijhaar EJ, Kleijne JA, Van Loon AM, Nievers MG, Schipper H, et al. (1996). Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 43:44-48.
95. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP, et al. (1999). Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 179:612-618.
96. Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, et al. (1992). Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection. Int J Cancer 50:45-48.
97. +) T-cell responses that home to the tumor site. J Virol 75:9654-9664.
98. Leachman SA, Tigelaar RE, Shlyankevich M, Slade MD, Irwin M, Chang E, et al. (2000). Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus - rabbit model. J Virol 74:8700-8708.
99. Leachman SA, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W, et al. (2002). Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 76:7616-7624.
100. Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP (2000). Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60:51-55.
101. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August T, Pardoll DM, et al. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26.
102. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO (1992). Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187:612-619.
103. Lin YL, Borenstein LA, Ahmed R, Wettstein FO (1993). Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J Virol 67:4154-4162.
104. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM (2001). Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92:805-813.
105. Ling M, Kanayama M, Roden R, Wu TC (2000). Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J Biomed Sci 7:341-356.
106. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, et al. (2000). Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74:2888-2894.
107. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH (2001a). Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20:862-869.
108. Liu Y, Chiriva-Internati M, Grizzi F, Salati E, Roman JJ, Lim S, et al. (2001b). Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther 8:948-957.
109. Londono LP, Chatfield S, Tindle RW, Herd K, Gao XM, Frazer I, et al. (1996). Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine 14:545-552.
110. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, et al. (1997). Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176:1141-1145.
111. Lowy DR, Schiller JT (1999). Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta 1423:M1-M8.
112. Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen DP, et al. (1994). DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 125:625-638.
113. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297-1302.
114. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, et al. (1997). Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 15:94-103.
115. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E (2000). Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89:300-304.
116. Meneguzzi G, Cerni C, Kieny MP, Lathe R (1991). Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181:62-69.
117. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M (2002). Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294:47-59.
118. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. (2001). Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125-1131.
119. Mounts P, Shah KV, Kashima H (1982). Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci USA 79:5425-5429.
120. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. (2000). A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406-3416.
121. + T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59:1184-1187.
122. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, et al. (1997). Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 65:3328-3336.
123. Nasseri M, Gage JR, Lorincz A, Wettstein FO (1991). Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7. Virology 184:131-140.
124. Osen W, Peiler T, Ohlschlager P, Caldeira S, Faath S, Michel N, et al. (2001). A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19:4276-4286.
125. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM (1995). Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 18:86-94.
126. Pan K, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y (1995). A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med 1:471-477.
127. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP (1997). Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 79:595-604.
128. Peng S, Frazer IH, Fernando GJ, Zhou J (1998). Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240:147-157.
129. Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM (1992). Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66:2418-2427.
130. Pintos J, Franco EL, Black MJ, Bergeron J, Arella M (1999). Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 85:1903-1909.
131. Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, Hariharan MJ, et al. (1999). Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci USA 96:4598-4603.
132. + T cells after gene gun immunization. J Exp Med 188:1075-1082.
133. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF (1997). Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401.
134. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, et al. (1995). Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934-5943.
135. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, et al. (2000). Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255-266.
136. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D (2001). Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 279:354-360.
137. Robinson HL (1997). Nucleic acid vaccines: an overview. Vaccine 15:785-787.
138. Robinson HL, Torres CA (1997). DNA vaccines. Semin Immunol 9:271-283.
139. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT (1996). Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70:3298-3301.
140. th, Fallon R, Inglis S, Lowy DR, Schiller JT (2000). Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270:254-257.
141. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, et al. (1997). Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3:849-854.
142. Rossi JL, Gissman L, Jansen K, Muller M (2000). Assembly of infectious human papillomavirus type 16 virus-like particle in Saccharomyces cerevisiae. Hum Gene Ther 11:1165-1176.
143. Rudolf MP, Fausch SC, Da Silva DM, Kast WM (2001a). Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 166:5917-5924.
144. Rudolf MP, Man S, Melief CJ, Sette A, Kast WM (2001b). Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 7:788s-795s.
145. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM (1996). Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin β subunit. Infect Immun 64:1272-1283.
146. Sarkar AK, Tortolero-Luna G, Nehete PN, Arlinghaus RB, Mitchell MF, Sastry KJ (1995). Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. Viral Immunol 8:165-174.
147. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, et al. (1995). Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206:126-135.
148. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA (1991). The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 164:593-599.
149. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, et al. (1999). Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 81:881-888.
150. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG (1991). Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol 21:2649-2654.
151. Schiller JT (1999). Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 5:209-215.
152. Schirmbeck R, Bohm W, Melber K, Reimann J (1995). Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J Immunol 155:4676-4684.
153. Schreckenberger C, Sethupathi P, Kanjanahaluethai A, Muller M, Zhou J, Gissmann L, et al. (2000). Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine 19:227-233.
154. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM (2001). Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 125:1-9.
155. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. (1985). Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114.
156. Selvakumar R, Borenstein LA, Lin YL, Ahmed R, Wettstein FO (1995). Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 69:602-605.
157. Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK (1998). Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 17:372-376.
158. Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L (1999). Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 73:7877-7881.
159. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV (2003). Condyloma in pregnancy is strongly predictive of juvenile onset recurrent respiratory papillomatosis. Obstet Gynecol 101:645-652.
160. Smahel M, Sima P, Ludvikova V, Vonka V (2001). Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281:231-238.
161. Snijders PJ, Meijer CJ, van den Brule AJ, Schrijnemakers HF, Snow GB, Walboomers JM (1992). Human papillomavirus (HPV) type 16 and 33 E6/E7 region transcripts in tonsillar carcinomas can originate from integrated and episomal HPV DNA. J Gen Virol 73(Pt 8):2059-2066.
162. Snijders PJ, Scholes AG, Hart CA, Jones AS, Vaughan ED, Woolgar JA, et al. (1996). Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinoma of the head and neck. Int J Cancer 66:464-469.
163. Srivastava PK, Udono H (1994). Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 6:728-732.
164. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL (1998). Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8:657-665.
165. Stanley MA, Moore RA, Nicholls PK, Santos EB, Thomsen L, Parry N, et al. (2001). Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19:2783-2792.
166. Steenbergen RD, Hermsen MA, Walboomers JM, Joenje H, Arwert F, Meijer CJ, et al. (1995). Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Cancer Res 55:5465-5471.
167. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, et al. (1998). Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4:2103-2109.
168. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. (1995). Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553-11557.
169. Tagami H (1983). Regression phenomenon of numerous flat warts - an experiment on the nature of tumor immunity in man. Int J Dermatol 22:570-571.
170. Tan J, Yang NS, Turner JG, Niu GL, Maassab HF, Sun J, et al. (1999). Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Ther 6:331-339.
171. Tao MH, Levy R (1993). Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758.
172. Thompson HS, Davies ML, Holding FP, Fallon RE, Mann AE, O'Neill T, et al. (1999). Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 17:40-49.
173. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT (2000). Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 60:5456-5463.
174. Tindle RW, Croft S, Herd K, Malcolm K, Geczy AF, Stewart T, et al. (1995). A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin Exp Immunol 101:265-271.
175. Touze A, Coursaget P (1998). In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 26:1317-1323.
176. Tuting T (1999). The immunology of cutaneous DNA immunization. Curr Opin Mol Ther 1:216-225.
177. Tuting T, DeLeo AB, Lotze MT, Storkus WJ (1997). Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 27:2702-2707.
178. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, et al. (2001a). Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19:3652-3660.
179. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, et al. (2001b). Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91:612-618.
180. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, et al. (1999). Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35:946-952.
181. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B, et al. (2001). Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93:232-235.
182. Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T, Kovacs GR, et al. (2001a). Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 61:7861-7867.
183. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, et al. (2001b). Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166:5366-5373.
184. Vierboom MP, Feltkamp MC, Neisig A, Drijfhout JW, ter Schegget J, Neefjes JJ, et al. (1998). Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother 21:399-408.
185. Wang T-L, Ling M, Shih I-M, Pham T, Pai SI, Lu L, et al. (2000). Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 7:726-733.
186. Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, et al. (1996). Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer 67:303-310.
187. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM (1997). Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833-10837.
188. Wilczynski SP, Lin BT, Xie Y, Paz IB (1998). Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 152:145-156.
189. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM (1987). Granulocyte/macrophage colony-stimulating factor is essentialfor the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 166:1484-1498.
190. Wu TC (1994). Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 6:746-754.
191. Wu T-C, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, et al. (1995). Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc Natl Acad Sci USA 92:11671-11675.
192. Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV (1989). Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243:1188-1191.
193. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, et al. (1999). Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823-827.
194. Yoon H, Chung MK, Min SS, Lee HG, Yoo WD, Chung KT, et al. (1998). Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors. Virus Res 54:23-29.
195. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL, et al. (2001). Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 75:7848-7853.
196. Zehbe I, Wilander E, Delius H, Tommasino M (1998). Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58:829-833.
197. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, et al. (1996). Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 156:700-710.
198. Zhao KN, Sun XY, Frazer IH, Zhou J (1998). DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243:482-491.
199. Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991). Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251-257.
200. zur Hausen H (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342-350.